Molecular Partners AG
SIX:MOLN
Relative Value
The Relative Value of one MOLN stock under the Base Case scenario is 6.43 CHF. Compared to the current market price of 3.35 CHF, Molecular Partners AG is Undervalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
MOLN Competitors Multiples
Molecular Partners AG Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CH |
Molecular Partners AG
SIX:MOLN
|
110.1m CHF | 15.6 | -1.8 | 1.3 | 1.2 | ||
US |
Abbvie Inc
NYSE:ABBV
|
287.4B USD | 5.3 | 59.6 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
160.6B USD | 5.4 | 42.7 | 18.2 | 29.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.6B USD | 8.1 | 27.4 | 22.1 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.7B USD | 10.5 | 28.7 | 22.9 | 24 | ||
AU |
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.7 | 21.6 | 26.8 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.7B USD | 3 | 168.7 | 6.8 | 8.9 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.8B USD | 9.1 | -7.8 | -8.5 | -7.6 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.2B USD | 3.3 | 27.6 | 14.1 | 17.7 | ||
KR |
Celltrion Inc
KRX:068270
|
40.2T KRW | 18.5 | 75.1 | 45.9 | 63.2 |